Support Alert

Class 4 drug alert: certain Baxter Potassium Chloride containing intravenous infusions

Baxter Healthcare Limited has informed the MHRA that a quality defect has been identified with certain potassium chloride containing intravenous infusions where the front panel of a small number of infusion bags was found to be missing the red text. The red text highlights the presence of potassium chloride in the products formulation which is a risk-mitigating factor in the prevention of a potential mix-up with other solutions for infusion.

Further information, details of the affected batches and advice for healthcare professionals can be found on the MHRA website.


Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.